| Revision as of 22:48, 29 January 2012 editTimrollpickering (talk | contribs)Administrators354,032 editsm clean up using AWB← Previous edit | Revision as of 13:02, 24 February 2012 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report errors...Next edit → | ||
| Line 1: | Line 1: | ||
| {{Drugbox | {{Drugbox | ||
| | Verifiedfields = changed | | Verifiedfields = changed | ||
| ⚫ | | verifiedrevid = 477243410 | ||
| | Watchedfields = changed | |||
| ⚫ | | verifiedrevid = |
||
| | IUPAC_name = | | IUPAC_name = | ||
| | image = | | image = | ||
Revision as of 13:02, 24 February 2012
Pharmaceutical compound| Clinical data | |
|---|---|
| Trade names | Eylea |
| License data |
|
| Routes of administration | Injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C4318H6788N1164O1304S32 |
| Molar mass | 96.90 kDa g·mol |
| (what is this?) (verify) | |
Aflibercept is a fusion protein approved in the United States for the treatment of wet macular degeneration. It is under development for the treatment of cancer.
It is an inhibitor of vascular endothelial growth factor. It is designed to bind to VEGF-A, VEGF-B, and placental growth factor (PIGF).
Aflibercept is being co-developed by Sanofi-Aventis and Regeneron Pharmaceuticals.
Approvals and indications
In November 2011 the United States Food and Drug Administration approved aflibercept for the treatment of wet macular degeneration.
Clinical trials
In March 2011 Regeneron reported that aflibercept failed its primary endpoint of overall survival in the Vital phase III trial for second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), although it improved the secondary endpoint of progression-free survival.
In April 2011 Regeneron reported that aflibercept improved its primary endpoint of overall survival in the Velour phase III clinical trial for second-line treatment for metastatic colorectal cancer (mCRC).
Aflibercept is also in a phase III trial for hormone-refractory metastatic prostate cancer.
References
- Fraser HM, Wilson H, Silvestri A, Morris KD, Wiegand SJ (2008). "The Role of Vascular Endothelial Growth Factor and Estradiol in the Regulation of Endometrial Angiogenesis and Cell Proliferation in the Marmoset". Endocrinology. 149 (9): 4413–20. doi:10.1210/en.2008-0325. PMID 18499749.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - Duncan WC, van den Driesche S, Fraser HM (2008). "Inhibition of Vascular Endothelial Growth Factor in the Primate Ovary Up-Regulates Hypoxia-Inducible Factor-1{alpha} in the Follicle and Corpus Luteum". Endocrinology. 149 (7): 3313–20. doi:10.1210/en.2007-1649. PMID 18388198.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ "Regeneron and Sanofi-Aventis Report Positive Phase III mCRC Trial Data". 27 Apr 2011.
- FDA Approves Eylea for Macular Degeneration
- "Regeneron and Sanofi-Aventis Cancer Drug Misses Phase III Primary Endpoint but Meets Secondary Targets". 11 Mar 2011.
| Ophthalmologicals: ocular vascular disorder agents (S01L) | |
|---|---|
| Antineovascularisation agents | |
| Immunosuppressive drugs / Immunosuppressants (L04) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (initiation) |
| ||||||||||||||
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |